CB-103
- Limantrafin
- Soluble in DMSO
- MF: C15H18N2O
- MW: 242.32
Description
CB-103 is an orally available NOTCH pathway inhibitor. Exhibited anti-tumor efficacy in multiple in vivo models and patient-derived xenograft models. It is currently under evaluation as therapies for Advanced or Metastatic Solid Tumors and Hematological Malignancies.
More Information
| Parent CAS No. | 218457-67-1 |
|---|---|
| Chemical Name | 6-(4-tert-Butylphenoxy)pyridin-3-amine |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1C=C(OC2C=CC(N)=CN=2)C=CC=1C(C)(C)C |
| MFCD | N.A. |
| InChi | InChI=1S/C15H18N2O/c1-15(2,3)11-4-7-13(8-5-11)18-14-9-6-12(16)10-17-14/h4-10H,16H2,1-3H3 |
| InChiKey | WHIWGRCYMQLLAO-UHFFFAOYSA-N |
| CID | 2735289 |
| Short Description | PPI inhibitor |
References
- F Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. 2016 US9296682B2.
- R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.
- R Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1487 | γ-Secretase Inhibitor BZ |
From $99.00 |
| 1488 | γ-Secretase Inhibitor DBZ |
From $88.00 |
| 1971 | TAK 438 |
From $159.50 |
| 2117 | Begacestat |
From $93.50 |
| 2133 | iCRT5 |
From $99.00 |
| 2277 | FLI 06 |
From $104.50 |
| 2487 | Silibinin |
From $44.00 |
| 2521 | RO 4929097 |
From $148.50 |
| 2638 | LP-935509 |
From $143.00 |
| 2936 | NVS-ZP7-4 |
From $170.50 |
| 3061 | RBPJ inhibitor RIN1 |
From $132.00 |
| 3161 | Pantoprazole sodium |
From $55.00 |
| 3244 | Lansoprazole |
From $44.00 |
| 3589 | Soraprazan |
From $154.00 |
| 3663 | Rabeprazole sodium |
From $55.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.